Group 1 - The company announced the resignation of its chairman, CEO, and other key positions, effective December 7, 2025, with the board expressing respect for the decision and gratitude for contributions made during the tenure [1] - David McKee HAND has been appointed as the new chairman, and the board has initiated a search for a new CEO, considering both internal and external candidates [1] - The company assures that these leadership changes will not affect its existing strategies and daily operations, with a commitment to continue stable development [1] Group 2 - Since its establishment in 2015, the former CEO has focused on the long-term development and strategic layout of the company, leading it through a significant transformation in the pharmaceutical industry [2] - The company successfully transitioned from a pharmaceutical e-commerce platform to a leading enterprise in "AI + chronic disease management," and it went public on the Hong Kong Stock Exchange in 2024 [2] - The company aims to continue focusing on online chronic disease management, leveraging AI services to assist millions of patients and contributing to the "Healthy China 2030" initiative [2]
方舟健客：谢方敏任非执行董事 “AI+慢病管理”战略笃定前行